Condition: Prostate Cancer · Radiotherapy Side Effect · Metastatic Cancer · Sponsor: Umeå University
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.
This description comes directly from the study's public registry record.
Camilla Thellenberg Karlsson, MD, PhD · +46 90 785 3296 · camilla.thellenberg@umu.se
Karin Söderkvist, MD, PhD · +4690 785 00 00 · karin.soderkvist@umu.se
Always discuss trial participation with your own doctor first.
| Cancercenter University hospital of Umeå | Umeå, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04612907